Lilly strikes $8.8bn-plus alliance with China's Innovent Eli Lilly has deepened its ties with Chinese biopharma company Innovent Biologics, signing a seventh R&D with a $350m upfront payment.

#EliLilly has deepened its ties with #Chinesebiopharma company #InnoventBiologics, signing a seventh R&D #collaboration that includes a $350 million upfront payment.

pharmaphorum.com/news/lilly-s...

3) 8,5 milyar dolara kadar dönüm noktası ödemelerine ve satışlara bağlı kademeli telif gelirlerine hak kazanacak. Şirket, bu ortaklığın yalnızca lisanslama değil, ortak ilaç geliştirmeye dayalı kapsamlı bir inovasyon modeli sunduğunu belirtti. #InnoventBiologics #EliLilly

#InnoventBiologics has picked up approval in #China for Pecondle, its anti-IL-23p19 antibody, as a treatment for moderate-to-severe plaque #psoriasis in adults.

pharmaphorum.com/news/innoven...

34-35 PHARMA - Time capsule Time capsule. The ten groundbreaking drugs shaping 2025 and the future

#Vertex #Cysticfibrosis #AstraZeneca #DaiichiSankyo #lungcancer #breastcancer #painmanagement #Alnylam #Sanofi #Haemophilia #Genentech #Roche #MS #MSD #Hypercholesterolemia #Pfizer #InnoventBiologics #EliLilly #Obesity #type2diabetes #GSK #eosinophilicasthma #meningitisvaccine
zurl.co/bzBzK

Pressure rises on Novo as Innovent drug tops Ozempic Innovent's dual glucagon and GLP-1 agonist mazdutide outperforms Novo Nordisk's Ozempic in overweight people with diabetes.

#InnoventBiologics has upped the ante in the fast-growing #GLP1agonist market with clinical data for its #mazdutide candidate that showed it was more effective than Novo Nordisk's Ozempic in overweight people with #type2diabetes.

pharmaphorum.com/news/pressur...